WO2009017719A8 - Modulators of ccr9 receptor and methods of use thereof - Google Patents

Modulators of ccr9 receptor and methods of use thereof Download PDF

Info

Publication number
WO2009017719A8
WO2009017719A8 PCT/US2008/009142 US2008009142W WO2009017719A8 WO 2009017719 A8 WO2009017719 A8 WO 2009017719A8 US 2008009142 W US2008009142 W US 2008009142W WO 2009017719 A8 WO2009017719 A8 WO 2009017719A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulators
ccr9 receptor
compounds
ccr9
Prior art date
Application number
PCT/US2008/009142
Other languages
French (fr)
Other versions
WO2009017719A2 (en
WO2009017719A3 (en
Inventor
Eric C. Anderson
Ronald J. Biediger
Jie Chen
Brian Dupre
Pedro Lory
Robert V. Market
Keith A. Monk
Michael M. Savage
Reginald Tennyson
Brandon M. Young
Original Assignee
Encysive Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals, Inc. filed Critical Encysive Pharmaceuticals, Inc.
Priority to MX2010001187A priority Critical patent/MX2010001187A/en
Priority to EP08794832A priority patent/EP2220065A2/en
Priority to CA2692013A priority patent/CA2692013C/en
Priority to AU2008282903A priority patent/AU2008282903B2/en
Publication of WO2009017719A2 publication Critical patent/WO2009017719A2/en
Publication of WO2009017719A3 publication Critical patent/WO2009017719A3/en
Publication of WO2009017719A8 publication Critical patent/WO2009017719A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.
PCT/US2008/009142 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof WO2009017719A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2010001187A MX2010001187A (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof.
EP08794832A EP2220065A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof
CA2692013A CA2692013C (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof
AU2008282903A AU2008282903B2 (en) 2007-07-30 2008-07-28 Modulators of CCR9 receptor and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96264007P 2007-07-30 2007-07-30
US60/962,640 2007-07-30

Publications (3)

Publication Number Publication Date
WO2009017719A2 WO2009017719A2 (en) 2009-02-05
WO2009017719A3 WO2009017719A3 (en) 2009-04-23
WO2009017719A8 true WO2009017719A8 (en) 2010-02-11

Family

ID=40305125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009142 WO2009017719A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof

Country Status (7)

Country Link
EP (1) EP2220065A2 (en)
KR (1) KR20100033418A (en)
AU (1) AU2008282903B2 (en)
CA (1) CA2692013C (en)
MX (1) MX2010001187A (en)
SG (1) SG183667A1 (en)
WO (1) WO2009017719A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53941B1 (en) 2009-01-12 2015-08-31 Pfizer Limited Sulfonamide derivatives
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
WO2012051318A1 (en) * 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
CN118201912A (en) * 2021-10-28 2024-06-14 四国化成工业株式会社 Thiophene compound, synthesis method thereof and composition containing thiophene compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129148A0 (en) * 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP3972163B2 (en) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 Phosphonic acid diester derivatives
EP1610753A4 (en) * 2003-02-20 2007-07-04 Encysive Pharmaceuticals Inc Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists

Also Published As

Publication number Publication date
EP2220065A2 (en) 2010-08-25
AU2008282903A1 (en) 2009-02-05
SG183667A1 (en) 2012-09-27
MX2010001187A (en) 2010-03-04
AU2008282903B2 (en) 2011-06-30
WO2009017719A2 (en) 2009-02-05
WO2009017719A3 (en) 2009-04-23
CA2692013C (en) 2012-08-28
CA2692013A1 (en) 2009-02-05
KR20100033418A (en) 2010-03-29

Similar Documents

Publication Publication Date Title
NL301145I1 (en)
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
MX2008011684A (en) Imidazolothiazole compounds for the treatment of disease.
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
EA201001329A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
TW200716624A (en) Compounds for modulating TRPV3 function
EP2542254A4 (en) Secondary structure stabilized nmda receptor modulators and uses thereof
UA98629C2 (en) Compounds and methods for kinase modulation
WO2007109330A3 (en) S1p receptor modulating compounds
WO2007056124A3 (en) Compounds for modulating trpv3 function
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2010021693A3 (en) Mif modulators
IL192868A0 (en) 1,4-di substituted 3-cyano- pyridone perivatives and their use as positive mglur2-receptor modulators
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
MY159955A (en) Certain chemical entities, compositions and methods
EP2354224A4 (en) Novel protein having fructosyl valyl histidine oxidase activity and modified product thereof, and use of the protein or the modified product
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2010068710A3 (en) Kinase inhibitor compounds
MX2010002028A (en) Methods and compositions for modulating t cells.
EA201001330A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2010034015A3 (en) Modulating the alternative complement pathway

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2692013

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008282903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008794832

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 20107001995

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010519223

Country of ref document: JP

Ref document number: MX/A/2010/001187

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2008282903

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1285/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase in:

Ref country code: JP